Table 3.
New research studies should include: |
1. Standardized measures for clinical and patient reported outcomes: |
Clinical outcomes can be reported as sputum conversion rate or cure and mortality rates at the end of treatment |
A range of patient-reported measures can be used: PREMs, PROMs, QALY, MOS-HIV Health Survey, and Karnofsky score |
2. Person-centered framework that acknowledges different comorbidities and treatment adverse events |
3. Strategies to minimize toxicity (e.g., intermittent administration) |
4. Cost-effectiveness and cost–benefit assessment |
In addition, new research studies should enable: |
5. Data registries on clinical relevance and patient’s treatment and outcome to be commenced and easily populated |
6. Epidemiological/surveillance data on likelihood of adverse events to be made easily available to patients and health-care providers |
Definition of abbreviations: MOS-HIV = Medical Outcomes Study HIV; PREMS = patient-reported experience measures; PROMS = patient-reported outcome measures; QALY = quality-adjusted life years.